---

Pancreatic Cancer: Genomics

Answer

Genomic testing in the National Health Service in England is provided through the NHS Genomic Medicine Service (NHS GMS) and delivered by a national genomic testing network of seven NHS Genomic Laboratory Hubs (GLHs). The NHS GLHs deliver testing as directed by the National Genomic Test Directory (NGTD), which includes tests for over 7,000 rare diseases and over 200 cancer clinical indications, including both whole genome sequencing (WGS) and non-WGS testing.

Genomic testing is available for all eligible patients across the whole of England. The NGTD sets out the eligibility criteria for patients to access testing as well as the genomic targets to be tested and the method that should be used. Genomic testing for pancreatic cancer is available under the M219 clinical indication code and delivered by all seven NHS GLHs.

NHS England captures Patient Level Contract Monitoring data across the NHS GMS to facilitate a national approach to reporting and validating activity data and turnaround times for the genomics element of the pathway. This national approach enables NHS England to understand activity volumes, detect any backlogs, and work with the NHS GLHs to implement improvement activities.

NHS England has been undertaking a procurement of NHS GMS Lead Providers to embed a new operating model for delivery of the NHS GMS from 2026. This includes a cancer genomics clinical function, which will bring together multi profession leadership to work with partners to embed and develop cancer genomics pathways.

Secondary information

Type

Written question

Reference

HL1191

Session

2026-27

Subjects

Screening Genomics Pancreatic cancer

Link

View this Written question on www.parliament.uk